Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Oncternal Therapeutics (ONCT) Insider Trading & Ownership

$1.70
0.00 (0.00%)
(As of 09:56 AM ET)

Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.20%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$92,735.84
Number Of
Insiders Selling
(Last 12 Months)
0

ONCT Insider Buying and Selling by Quarter

Oncternal Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56  
3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72  
2/23/2024David F HaleDirectorBuy714$9.04$6,454.56  
(Data available from 1/1/2013 forward)

ONCT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT.

11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings.

The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($4,350.00), David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($29,000.00), Richard G Vincent ($9,000.00), Robert James Wills ($86,281.28), and Salim Yazji ($4,300.00).

Insiders have purchased a total of 20,114 ONCT shares in the last 24 months for a total of $149,215.84 bought.



This page (NASDAQ:ONCT) was last updated on 9/20/2024 by MarketBeat.com Staff
From Our Partners